Biotech Values

[xavierprivas]

I bought MDGL yesterday @90.5. The Investor's Business Daily had a story
about the FDA draft on guidelines for NASH clinical trials that seems
to set a high bar.

There are 4 levels of liver fibrosis F1 through F4. Yesterday FDA draft
was for F4 (cirrhosis) and I actually agree with the FDA requirements.

MDGL, VKTX, ICPT drugs are for F2/F3 level of fibrosis and their trials
are well within the FDA draft guidelines (published sometime last year,
Dec 18 I think for F2/F3).